CACI International (CACI) had its price target lowered by Citigroup Inc. from $721.00 to $614.00. They now have a "neutral" rating on the stock.
PanGIA Biotech Announces Peer-Reviewed Study in Diagnostics Showing 97.8% Sensitivity in Detecting Prostate Cancer Using a Urine-Based Liquid Biopsy with Machine Learning [Yahoo! Finance]
CACI International (CACI) was upgraded by Wells Fargo & Company to "strong-buy".
CACI International (CACI) is now covered by Wells Fargo & Company. They set an "overweight" rating and a $275.00 price target on the stock.
CACI Wins US$85m Navy Deal Sharpening Cyber And Engineering Focus [Yahoo! Finance]